Mutations of the BRAF gene in human cancer
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS RAF MEK ERK MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS. Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The hotspot BRAF V600E mutation at codon 600 of exon 15 increases the activity of BRAF kinase by 130- to 700-fold [26, 93–95].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [95]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations occur in ∼10% of colorectal cancer (CRC) patients, leading to poor prognosis.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations are present in around 10% of advanced CRC patients and lead to constitutive activation of the MAPK pathway, drug resistance and a poor prognosis [1–4].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF mutations occur in roughly 5–15% of CRCs (1–3, 17)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [17]
In the citing paper
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [36]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“There has recently been marked success reported of an inhibitor (STI571) of the BCR-ABL kinase in the treatment of chronic myeloid leukaemi”
BackgroundIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015 · cited 1×
“To evaluate whether activating mutations of BRAF signal through MEK and ERK, we treated cells with the MEK1/2 inhibitor U0126 (ref”
MethodMeaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
BackgroundRequirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells
Mulcahy, L. S., Smith, M. R., & Stacey, D. W. (1985) · Nature · doi:10.1038/313241a0 · Cited by 878 · cited 1×
“Studies using injection of the RAS-neutralizing Y13-259 monoclonal antibody have previously shown that most normal cells examined and some tumour cells require RAS function for proliferation in cultur”
MethodThe Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735 · cited 1×
“The RAS–RAF–MEK–ERK–MAP kinase pathway mediates cellular responses to growth signal”
BackgroundIncreasing Complexity of the Ras Signaling Pathway
Vojtek, A. B., & Der, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19925 · Cited by 579
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationRas Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade
Avruch, J. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.127 · Cited by 391 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
Background
Cited by
Items 801–900 of 1,150
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Tian, J., Chen, J. H., Chao, S. X., Pelka, K., Giannakis, M., Hess, J., Burke, K., Jorgji, V., Sindurakar, P., Braverman, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02181-8 · Cited by 198
Mitofusin 2 Triggers Vascular Smooth Muscle Cell Apoptosis via Mitochondrial Death Pathway
Guo, X., Chen, K.-H., Guo, Y., Liao, H., Tang, J., & Xiao, R.-P. (2007) · Circulation Research · doi:10.1161/circresaha.107.157644 · Cited by 200
A federated ecosystem for sharing genomic, clinical data
The Global Alliance for Genomics and Health* (2016) · Science · doi:10.1126/science.aaf6162 · Cited by 206
Pan, W., Zhu, S., Qu, K., Meeth, K., Cheng, J., He, K., Ma, H., Liao, Y., Wen, X., Roden, C., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.020 · Cited by 198
“Human melanomas harbor activation mutations in BRAF in 65% of cases (Chin, 2003; Davies et al., 2002), which often co-occur with loss-of-function mutations in tumor suppressors such as PTEN and CDKN2A.”
Targeted Therapy in Melanoma and Mechanisms of Resistance
Czarnecka, A. M., Bartnik, E., Fiedorowicz, M., & Rutkowski, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134576 · Cited by 196
“BRAF mutations were discovered in about 50–60% of metastatic melanoma cases [13,14].”
BackgroundManagement of conjunctival malignant melanoma: a review and update
Wong, J. R., Nanji, A. A., Galor, A., & Karp, C. L. (2014) · Expert Review of Ophthalmology · doi:10.1586/17469899.2014.921119 · Cited by 194
“Vemurafenib and dabrafenib are highly selective BRAF-kinase inhibitors, a mutation found in 60% of cutaneous melanomas, primarily at the V600E position [158].”
BackgroundBRAF Signaling and Targeted Therapies in Melanoma
Dhomen, N., & Marais, R. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.04.001 · Cited by 195
Self-citationAhmed, M., Barbachano, Y., Riddell, A., Hickey, J., Newbold, K. L., Viros, A., Harrington, K. J., Marais, R., & Nutting, C. M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0129 · Cited by 201
“cases harbour activating point mutations [20].”
Self-citationHow to make a melanoma: what do we know of the primary clonal events?
Bennett, D. C. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2007.00433.x · Cited by 198
“Some commoner and well-known changes are, for example, activating mutations of BRAF (Davies et al., 2002), silencing of E-cadherin expression (Kuphal and Bosserhoff, 2006), and acquisition of telomerase activity (reviewed: Gray-Schopfer and Bennett, 2006).”
BackgroundKim, K. B., Cabanillas, M. E., Lazar, A. J., Williams, M. D., Sanders, D. L., Ilagan, J. L., Nolop, K., Lee, R. J., & Sherman, S. I. (2013) · Thyroid · doi:10.1089/thy.2013.0057 · Cited by 197
“This mutation mimics activated BRAF kinase protein, leading to phosphorylation of the downstream extracellular signal-regulated kinase kinase (MEK) and extracellular signal-regulated kinase (ERK1/2), tumor cell proliferation, and potentially loss of differentiated functions (17–19).”
Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation
Wellbrock, C., & Marais, R. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505059 · Cited by 196
“5 D, lanes 1, 2, 5, and 6) and in two melanoma cell lines that express oncogenic B-RAF (Davies et al., 2002), and this is accompanied by reduced proliferation (Fig.”
BackgroundInfluentialSelf-citationFrequent Alterations in the Expression of Serine/Threonine Kinases in Human Cancers
Capra, M., Nuciforo, P. G., Confalonieri, S., Quarto, M., Bianchi, M., Nebuloni, M., Boldorini, R., Pallotti, F., Viale, G., Gishizky, M. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3489 · Cited by 200
Kim, K. B., Sosman, J. A., Fruehauf, J. P., Linette, G. P., Markovic, S. N., McDermott, D. F., Weber, J. S., Nguyen, H., Cheverton, P., Chen, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.6270 · Cited by 196
BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Dahlman, K. B., Xia, J., Hutchinson, K., Ng, C., Hucks, D., Jia, P., Atefi, M., Su, Z., Branch, S., Lyle, P. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0097 · Cited by 198
“S8), although the L597R/Q mutants did so to a lesser extent, consistent with studies on an analogous L597V mutant (7).”
BackgroundThe identification of potent and selective imidazole-based inhibitors of B-Raf kinase
Takle, A. K., Brown, M. J. B., Davies, S., Dean, D. K., Francis, G., Gaiba, A., Hird, A. W., King, F. D., Lovell, P. J., Naylor, A., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.09.072 · Cited by 194
Stanly, C., Alfieri, M., Ambrosone, A., Leone, A., Fiume, I., & Pocsfalvi, G. (2020) · Cells · doi:10.3390/cells9122722 · Cited by 192
Oncogenes in Cell Survival and Cell Death
Shortt, J., & Johnstone, R. W. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009829 · Cited by 193
“Oncogenic RAF mutations are implicated in the pathogenesis of melanoma and colorectal cancer (Davies et al. 2002).”
BackgroundAkt3-Mediated Resistance to Apoptosis in B-RAF–Targeted Melanoma Cells
Shao, Y., & Aplin, A. E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4471 · Cited by 194
“A significant advance in understanding the biology of melanoma was the identification of BRAF mutations in approximately 60% of these tumors (1).”
BackgroundSumimoto, H., Miyagishi, M., Miyoshi, H., Yamagata, S., Shimizu, A., Taira, K., & Kawakami, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207812 · Cited by 194
“This may be explained by 10–12-fold higher kinase activity of the mutated BRAF than wild-type BRAF as previously reported (Davies et al., 2002).”
BackgroundInfluentialParadoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
Gibney, G. T., Messina, J. L., Fedorenko, I. V., Sondak, V. K., & Smalley, K. S. M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.83 · Cited by 197
Genetic Alterations in Signaling Pathways in Melanoma
Haluska, F. G., Tsao, H., Wu, H., Haluska, F. S., Lazar, A., & Goel, V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2518 · Cited by 198
Wang, Y. F., Jiang, C. C., Kiejda, K. A., Gillespie, S., Zhang, X. D., & Hersey, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0665 · Cited by 194
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development
Cheung, M., Sharma, A., Madhunapantula, S. V., & Robertson, G. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5867 · Cited by 196
“A single-base mutation converting T to A at nucleotide 1,799 of B-Raf, substituting a valine for a glutamic acid at codon 600 (V600E) in exon 15, is the most prominent mutation ( 12 ) and is acquired but not inherited during development of sporadic melanomas (17–19).”
BackgroundControl of MAPK signalling: from complexity to what really matters
Hornberg, J. J., Binder, B., Bruggeman, F. J., Schoeberl, B., Heinrich, R., & Westerhoff, H. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208817 · Cited by 199
“This is in accordance with the experimentally verified claim that Raf is a potent oncogene (Rapp et al., 1983; Magnuson et al., 1994; Davies et al., 2002).”
BackgroundResultPrognostic and Predictive Biomarkers: Tools in Personalized Oncology
Nalejska, E., Mączyńska, E., & Lewandowska, M. A. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0077-9 · Cited by 188
“1799 T[A) [74].”
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations
Chudnovsky, Y., Adams, A. E., Robbins, P. B., Lin, Q., & Khavari, P. A. (2005) · Nature Genetics · doi:10.1038/ng1586 · Cited by 198
“Induction of Ras and Raf can be caused by active N-Ras and B-Raf mutants as well as by gene amplificatio”
BackgroundNumber of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma
Thomas, N. E., Edmiston, S. N., Alexander, A., Millikan, R. C., Groben, P. A., Hao, H., Tolbert, D., Berwick, M., Busam, K., Begg, C. B., et al. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-1038 · Cited by 192
“2) in exon 15 with the remainder in exon 11 (9).”
BackgroundSurvival improvement for patients with metastatic colorectal cancer over twenty years
Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00353-4 · Cited by 192
Fan, T., Jiang, S., Chung, N., Alikhan, A., Ni, C., Lee, C.-C. R., & Hornyak, T. J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0511 · Cited by 193
“BRAF and activating mutations at codon 61 in NRAS, both found frequently in melanoma (7, 8), are also associated with acquired (9) and congenital (10) melanocytic nevi, respectively.”
BackgroundMolecular responses to hypoxia in tumor cells.
Kunz, M., & Ibrahim, S. M. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-23 · Cited by 224
BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
Proietti, I., Skroza, N., Michelini, S., Mambrin, A., Balduzzi, V., Bernardini, N., Marchesiello, A., Tolino, E., Volpe, S., Maddalena, P., et al. (2020) · Cancers · doi:10.3390/cancers12071823 · Cited by 186
“The second most common mutation involves V600K which has been reported in approximately 8% of melanomas [8,13].”
BackgroundSerrated neoplasia—role in colorectal carcinogenesis and clinical implications
IJspeert, J. E. G., Vermeulen, L., Meijer, G. A., & Dekker, E. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.73 · Cited by 190
Schuierer, M. M., Bataille, F., Hagan, S., Kolch, W., & Bosserhoff, A.-K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3861 · Cited by 193
“Recently, it was shown that mutations primarily occur in the BRCA2-associated factor (BRAF) gene (6, 7).”
BackgroundHIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase
Sendoel, A., Kohler, I., Fellmann, C., Lowe, S. W., & Hengartner, M. O. (2010) · Nature · doi:10.1038/nature09141 · Cited by 192
Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma
Namkoong, J., Shin, S.-S., Lee, H. J., Marín, Y. E., Wall, B. A., Goydos, J. S., & Chen, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3665 · Cited by 192
“Functional GRM1 in Human Melanoma Cells A constitutively activated MAPK pathway, specifically extracellular-signal regulated kinase (ERK), has been reported for human melanoma cell lines and biopsies [45, 69, 85].”
BackgroundRas/Mitogen-Activated Protein Kinase Signaling Activates Ets-1 and Ets-2 by CBP/p300 Recruitment
Foulds, C. E., Nelson, M. L., Blaszczak, A. G., & Graves, B. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10954-10964.2004 · Cited by 190
“CBP/p300 recruitment. To date, constitutive Ras/MAPK signaling can result from activating mutations in either ras or B-raf genes ( 6 , 8). The resultant oncogenic proteins can affect cellular processes associated with malignancy, such as stimulated proliferation, inhibited apoptosis, induced angiogenesis, and increase…”
BackgroundMutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells
Koelsche, C., Wöhrer, A., Jeibmann, A., Schittenhelm, J., Schindler, G., Preusser, M., Lasitschka, F., von Deimling, A., & Capper, D. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1100-2 · Cited by 191
“Mutations in BRAF have been detected in up to 7 % of human neoplasms [10].”
BackgroundmTOR signaling in glioblastoma: lessons learned from bench to bedside
Akhavan, D., Cloughesy, T. F., & Mischel, P. S. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq052 · Cited by 191
“Recent work demonstrates that the BRAF V600E mutation, a common hyperactivating mutation in melanoma and other cancer types [73–75], forms a complex with Erk and LKB1 promoting phosphorylation and inactivation of LKB1 by ERK, thus functionally relieving LKB1’s ability to activate AMPK and thus”
Melanoma: What do all the mutations mean?
Davis, E. J., Johnson, D. B., Sosman, J. A., & Chandra, S. (2018) · Cancer · doi:10.1002/cncr.31345 · Cited by 180
“In 2002, BRAF mutations were found to occur frequently in up to 66% of patients with melanoma.(36) These activating mutations in BRAF result in constitutive activation of kinase function, independent of upstream signaling from RAS.”
BackgroundDummer, R., Flaherty, K. T., Robert, C., Arance, A., de Groot, J. W. B., Garbe, C., Gogas, H. J., Gutzmer, R., Krajsová, I., Liszkay, G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02659 · Cited by 187
“INTRODUCTION Approximately 50% of melanomas contain BRAF V600 mutations, which constitutively activate the mitogenactivated protein kinase pathway, driving cellular proliferation and disease progression.(1,2) Combination treatment with BRAF andMEK inhibitors (BRAFi andMEKi) is now the standard of care for treatingBRAF…”
BackgroundMicroarray expression profiling in melanoma reveals a BRAF mutation signature
Pavey, S., Johansson, P., Packer, L., Taylor, J., Stark, M., Pollock, P. M., Walker, G. J., Boyle, G. M., Harper, U., Cozzi, S.-J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207563 · Cited by 183
“Since all BRAF mutations to date have been reported to occur in exons 11 and 15 (Brose et al., 2002; Davies et al., 2002; Naoki et al., 2002; Yuen et al., 2002), each line was screened for variants in these exons by PCR sequencing.”
BackgroundMethodResultInfluentialHocker, T. L., Singh, M. K., & Tsao, H. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.226 · Cited by 189
“One of the first and perhaps most substantial findings was the discovery of a highly recurrent mutation in BRAF among different cancer types including melanoma (Davies et al., 2002).”
BackgroundThe Genomic Landscape of Childhood and Adolescent Melanoma
Lu, C., Zhang, J., Nagahawatte, P., Easton, J., Lee, S., Liu, Z., Ding, L., Wyczalkowski, M. A., Valentine, M., Navid, F., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.425 · Cited by 186
“It has been shown that B60% of adult melanoma carry an oncogenic BRAF V600 and B20% carry an oncogenic NRAS mutation (Davies et al., 2002; Lee et al., 2011).”
BackgroundSelf-citationStark, M. S., Woods, S. L., Gartside, M. G., Bonazzi, V. F., Dutton-Regester, K., Aoude, L. G., Chow, D., Sereduk, C., Niemi, N. M., Tang, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.1041 · Cited by 191
“, and BRAF , encoding a MAP3K, is the most commonly mutated gene in melanom”
BackgroundMolecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities
Wang, W., Kandimalla, R., Huang, H., Zhu, L., Li, Y., Gao, F., Goel, A., & Wang, X. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.002 · Cited by 187
“Furthermore, an additional highlight was that CRCs with C2, C3, C4 and C6 may arise from the serrated neoplasia pathway, while C1 and C5 subtypes of cancers primarily developed through conventional adenomas.”
BackgroundInfluentialLiu, H., He, Z., von Rütte, T., Yousefi, S., Hunger, R. E., & Simon, H.-U. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005864 · Cited by 188
Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
Solit, D. B., Osman, I., Polsky, D., Panageas, K. S., Daud, A., Goydos, J. S., Teitcher, J., Wolchok, J. D., Germino, F. J., Krown, S. E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1002 · Cited by 190
The Role of PGC1α in Cancer Metabolism and its Therapeutic Implications
Tan, Z., Luo, X., Xiao, L., Tang, M., Bode, A. M., Dong, Z., & Cao, Y. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0621 · Cited by 189
“The V600E BRAF mutation plays a critical role in melanomagenesis by constitutively activating the MAPK signaling pathways (62, 63).”
BackgroundTargeting the ERK Signaling Pathway in Melanoma
Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 184
“1799T > A in exon 15 [113]; this mutation increases the BRAF kinase activity by about 700-fold over WTBRAF, and more than 500-fold over the activated WTBRAF [89].”
BackgroundLow-grade developmental and epilepsy associated brain tumors: a critical update 2020
Slegers, R. J., & Blumcke, I. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00904-x · Cited by 187
“mutation in 2002 in several tumor entities, especially in malignant melanomas [22].”
BackgroundShort interfering RNAs as a tool for cancer gene therapy
Izquierdo, M. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700791 · Cited by 190
“The oncogene B - raf was found to be mutated in 59% of melanoma cell lines, in 80% of short-term melanoma cell cultures and 66% of uncultured melanomas”
BackgroundMolecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Fois, S. S., Paliogiannis, P., Zinellu, A., Fois, A. G., Cossu, A., & Palmieri, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020612 · Cited by 180
Self-citationFunctional and therapeutic significance of Akt deregulation in malignant melanoma
Robertson, G. P. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1577-9 · Cited by 189
“One example could be interaction between Akt and a protein called BRAF [114], which in melanoma is mutated to a constitutively active form [115,116].”
BackgroundAcquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
Fedorenko, I. V., Paraiso, K. H. T., & Smalley, K. S. M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.015 · Cited by 186
“2002 was a landmark event in the understanding of melanoma biology [2].”
BackgroundEGFR Signaling in Colorectal Carcinoma
Krasinskas, A. M. (2011) · Pathology Research International · doi:10.4061/2011/932932 · Cited by 184
“The most frequently reported BRAF mutation is a valine-to-glutamic acid amino acid (V600E) substitution [45].”
BackgroundHall, A., Meyle, K. D., Lange, M. K., Klima, M., Sanderhoff, M., Dahl, C., Abildgaard, C., Thorup, K., Moghimi, S. M., Jensen, P. B., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.965 · Cited by 188
Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination
Sanborn, J. Z., Chung, J., Purdom, E., Wang, N. J., Kakavand, H., Wilmott, J. S., Butler, T., Thompson, J. F., Mann, G. J., Haydu, L. E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508074112 · Cited by 192
“Davies H, et al. (2002) Mutations of the BRAF gene in human cancer.”
BackgroundInfluentialHonecker, F., Wermann, H., Mayer, F., Gillis, A. J. M., Stoop, H., van Gurp, R. J. L. M., Oechsle, K., Steyerberg, E., Hartmann, J. T., Dinjens, W. N. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8623 · Cited by 188
“Other studies could not demonstrate mutated BRAF in GCT tumor samples or cell lines.(14,15) Whereas in a series of GCTs from 44 patients who experienced treatment failure with cisplatinbased chemotherapy, only wild-type KRAS was detected,(16) BRAF mutation status has so far not been correlated with treatment outcome i…”
ResultSala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G. E., & Gambacorti-Passerini, C. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2001 · Cited by 188
“melanoma, colorectal cancer, and ovarian cancer (1).”
Schreuer, M., Jansen, Y., Planken, S., Chevolet, I., Seremet, T., Kruse, V., & Neyns, B. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30171-7 · Cited by 184
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Gautschi, O., Milia, J., Cabarrou, B., Bluthgen, M.-V., Besse, B., Smit, E. F., Wolf, J., Peters, S., Früh, M., Koeberle, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000625 · Cited by 186
“The most frequent BRAF mutation in cancer overall is V600E, leading to constitutive activation of B-Raf kinase and its downstream target extracellular regulated MAP kinase (ERK), whereas other BRAF mutations have also been described.(7) The clinical development of BRAF V600E specific small inhibitors was pioneered in…”
BackgroundTejpar, S., Bertagnolli, M., Bosman, F., Lenz, H.-J., Garraway, L., Waldman, F., Warren, R., Bild, A., Collins-Brennan, D., Hahn, H., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0233 · Cited by 185
BRAF mutations in an Italian cohort of thyroid cancers
Fugazzola, L., Mannavola, D., Cirello, V., Vannucchi, G., Muzza, M., Vicentini, L., & Beck‐Peccoz, P. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02089.x · Cited by 184
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response
Pratilas, C. A., & Solit, D. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3064 · Cited by 183
“Activating BRAF mutations are found clustered within the P-loop (exon 11) and activation segment (exon 15) of the kinase domain, and a single point mutation, V600E, accounts for approximately 90% of cases (12, 14).”
BackgroundSensi, M., Nicolini, G., Petti, C., Bersani, I., Lozupone, F., Molla, A., Vegetti, C., Nonaka, D., Mortarini, R., Parmiani, G., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209379 · Cited by 183
“In more than 90% of melanomas with a mutated BRAF, a single-base mutation at nucleotide position 1799 of exon 15 leads to a valine to glutamate (V600E) substitution (Davies et al., 2002; Mercer and Pritchard, 2003; Garnett and Marais, 2004; Gray-Schopfer et al., 2005).”
BackgroundMethodInfluentialResistance to BRAF inhibitors induces glutamine dependency in melanoma cells
Baenke, F., Chaneton, B., Smith, M., Van Den Broek, N., Hogan, K., Tang, H., Viros, A., Martin, M., Galbraith, L., Girotti, M. R., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.003 · Cited by 181
Self-citationValidation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology
Cottrell, C. E., Al-Kateb, H., Bredemeyer, A. J., Duncavage, E. J., Spencer, D. H., Abel, H. J., Lockwood, C. M., Hagemann, I. S., O’Guin, S. M., Burcea, L. C., et al. (2014) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.10.002 · Cited by 184
Demographic history, selection and functional diversity of the canine genome
Ostrander, E. A., Wayne, R. K., Freedman, A. H., & Davis, B. W. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.67 · Cited by 185
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
Du, W., & Elemento, O. (2015) · Oncogene · doi:10.1038/onc.2014.291 · Cited by 182
A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal
Catalanotti, F., Reyes, G., Jesenberger, V., Galabova-Kovacs, G., de Matos Simoes, R., Carugo, O., & Baccarini, M. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1564 · Cited by 182
“, whereas acquired somatic mutations have been found in a vast variety of cancer”
BackgroundKRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors
Miranda, C., Nucifora, M., Molinari, F., Conca, E., Anania, M. C., Bordoni, A., Saletti, P., Mazzucchelli, L., Pilotti, S., Pierotti, M. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2230 · Cited by 181
“Age >65 43 (58) 65 31 (42) Gender Male 43 (58) Female 31 (42) Tumor location Stomach 43 (58) Small bowel 19 (26) Others 12 (16) Tumor size <2 19 (26) 2 5 20 (27) 5 < 10 18 (24) 10 13 (18) unknown 4 (5) Risk of malignancies Very low 15 (20) Low 19 (26) Intermediate 11 (15) High 29 (39)”
Role of nuclear factor-κ B in melanoma
Amiri, K. I., & Richmond, A. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1579-7 · Cited by 180
“Whereas about 20% of melanoma appear to carry mutation in the N-Ras oncogene [94,95], over 60% were recently reported to contain mutation within the B-Raf gene [96,97].”
Pathology and genetics of thyroid carcinoma
DeLellis, R. A. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20700 · Cited by 181
“Among the isoforms of RAF kinase, BRAF appears to be the most potent activator of the MAPK pathway.”
BackgroundInfluentialRalGDS is required for tumor formation in a model of skin carcinogenesis
González-García, A., Pritchard, C. A., Paterson, H. F., Mavria, G., Stamp, G., & Marshall, C. J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.029 · Cited by 181
“While there is a large body of evidence supporting a key role for Raf/MAPK pathway in oncogenic Ras signaling, for example the restriction of Ras and BRAF mutations to the same tumor types and the mutual exclusivity of Ras and BRAF mutations (Davies et al. 2002), questions have been raised about the significance of Ra…”
BackgroundMethodSelf-citationKalady, M. F., DeJulius, K. L., Sanchez, J. A., Jarrar, A., Liu, X., Manilich, E., Skacel, M., & Church, J. M. (2012) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31823c08b3 · Cited by 163
“Evidence suggests that BRAF mutations, like KRAS mutations, result in uncontrolled, non– growth factor-dependent cellular proliferation.(18,19) Similar to the rationale that KRAS mutation precludes effective treatment with anti-EGFR drugs, the role of BRAF mutation and response to therapy is evolving.”
BackgroundThe World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe
Dimitriou, F., Krattinger, R., Ramelyte, E., Barysch, M. J., Micaletto, S., Dummer, R., & Goldinger, S. M. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0732-8 · Cited by 179
Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergo, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418829 · Cited by 180
Basolo, F., Torregrossa, L., Giannini, R., Miccoli, M., Lupi, C., Sensi, E., Berti, P., Elisei, R., Vitti, P., Baggiani, A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0337 · Cited by 182
“This mutation is very important because it leads to destabilization of the kinase encoded by the gene; it promotes a constitutively activated state, enhances BRAF kinase activity toward MAPK kinase, and promotes tumorigenesis through the MAPK pathway (6).”
BackgroundMittapalli, R. K., Vaidhyanathan, S., Dudek, A. Z., & Elmquist, W. F. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201475 · Cited by 179
“BRAF is a commonly mutated protein in melanoma, with ~80% carrying a V600E (BRAF) mutation (Davies et al., 2002).”
BackgroundWhich drug, and when, for patients with BRAF-mutant melanoma?
Jang, S., & Atkins, M. B. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70539-9 · Cited by 182
Roh, M. R., Eliades, P., Gupta, S., & Tsao, H. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12412 · Cited by 180
“…BRAF mutations at a V660E in the kinase domain of exon 15 has been reported in melanomas and melanocytic nevi, suggesting mutational activation of the RAS/RAF/MEK/ERK pathway is a critical step in the development of these melanocytic tumors (Davies et al., 2002; Pollock et al., 2003) (Figure 1).”
BackgroundInfluentialPignochino, Y., Grignani, G., Cavalloni, G., Motta, M., Tapparo, M., Bruno, S., Bottos, A., Gammaitoni, L., Migliardi, G., Camussi, G., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-118 · Cited by 180
“A B-RAF mutation occur in approximately 8% of human tumours (melanoma, papillary thyroid cancer and colon cancer) and in over 80% of cases it is represented by a single base-pair substitution in exon 15 at codon 600 (V600E) [28].”
Koorstra, J.-B. M., Hustinx, S. R., Offerhaus, G. J. A., & Maitra, A. (2008) · Pancreatology · doi:10.1159/000123838 · Cited by 183
Switching on kinases: oncogenic activation of BRAF and the PDGFR family
Dibb, N. J., Dilworth, S. M., & Mol, C. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1434 · Cited by 179
“A primary goal of the CGP is to provide a more complete picture of the number and patterns of mutations underlying human oncogenesi”
BackgroundProtein Kinase Inhibitors as a Therapeutic Modality
Levitzki, A. (2003) · Accounts of Chemical Research · doi:10.1021/ar0201207 · Cited by 178
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergö, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18829 · Cited by 180
“Activating mutations in B-Raf have been identified in 66% of malignant melanomas (43).”
Zhong, X., & Rescorla, F. J. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2011.10.005 · Cited by 180
Palmieri, G., Capone, M., Ascierto, M. L., Gentilcore, G., Stroncek, D. F., Casula, M., Sini, M. C., Palla, M., Mozzillo, N., & Ascierto, P. A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-86 · Cited by 177
Self-citationLovat, P. E., Corazzari, M., Armstrong, J. L., Martin, S., Pagliarini, V., Hill, D., Brown, A. M., Piacentini, M., Birch-Machin, M. A., & Redfern, C. P. F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0035 · Cited by 177
“The induction of ER stress in human melanoma cell lines CHL-1, A375, and WM266-4 (17) in response to fenretinide or velcade at clinically achievable concentrations (18, 19) was confirmed by the marked induction of mRNA for GADD34 (protein phosphatase 1, regulatory subunit 15A) and the stress transcription factor ATF4…”
InfluentialThe genetics of uveal melanoma: an emerging framework for targeted therapy
Harbour, J. W. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00979.x · Cited by 178
“Activating mutations in BRAF and NRAS are common in some types of cutaneous melanoma, but are distinctively rare in UM (Cruz et al., 2003; Curtin et al., 2005; Davies et al., 2002; Mooy et al., 1991; Rimoldi et al., 2003; Soparker et al., 1993; Weber et al., 2003; Zuidervaart et al., 2005).”
BackgroundRegulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
Liu, R., Zhang, T., Zhu, G., & Xing, M. (2018) · Nature Communications · doi:10.1038/s41467-018-03033-1 · Cited by 178
BRAF Mutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas
Lima, J., Trovisco, V., Soares, P., Máximo, V., Magalhães, J., Salvatore, G., Santoro, M., Bogdanova, T., Tronko, M., Abrosimov, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032224 · Cited by 181
Absence of BRAF mutations in UV-protected mucosal melanomas
Edwards, R. H., Ward, M. R., Wu, H., Medina, C. A., Brose, M. S., Volpe, P., Nussen-Lee, S., Haupt, H. M., Martin, A. M., Herlyn, M., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.016667 · Cited by 178
Self-citationPrimary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
Cappuzzo, F., Varella-Garcia, M., Finocchiaro, G., Skokan, M., Gajapathy, S., Carnaghi, C., Rimassa, L., Rossi, E., Ligorio, C., Di Tommaso, L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604439 · Cited by 178
“BRAF mutations were identified in 66% of melanomas, and in smaller percentage in other human cancers including colorectal (Davies et al, 2002).”
BackgroundSystematic classification of melanoma cells by phenotype‐specific gene expression mapping
Widmer, D. S., Cheng, P. F., Eichhoff, O. M., Belloni, B. C., Zipser, M. C., Schlegel, N. C., Javelaud, D., Mauviel, A., Dummer, R., & Hoek, K. S. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00986.x · Cited by 185
“Phenotype is independent of BRAF mutation status The BRAFV600E mutation is a frequent occurrence in melanoma, being present in more than half of all samples tested (Davies et al., 2002).”
BackgroundCutaneous adverse effects of targeted therapies
Macdonald, J. B., Macdonald, B., Golitz, L. E., LoRusso, P., & Sekulic, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.033 · Cited by 177
“Malignancies with the highest association with BRAF mutation, the so-called BRAFomas, include hairy cell leukemia (100%), melanoma (;50%), papillary thyroid (;40%), serous ovarian (;30%), colorectal (\10%), and prostate (\10%).(4,5) The majority of BRAF mutant melanomas contain a substitution of glutamic acid for vali…”
BackgroundResistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Su, F., Bradley, W. D., Wang, Q., Yang, H., Xu, L., Higgins, B., Kolinsky, K., Packman, K., Kim, M. J., Trunzer, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1875 · Cited by 179
“The BRAF oncogene is mutated in approximately 8% of all human tumors; however, the prevalence is much higher in melanoma, where amutation is documented inmore than 50% of all melanoma (1).”
BackgroundWoodman, S. E., Trent, J. C., Stemke-Hale, K., Lazar, A. J., Pricl, S., Pavan, G. M., Fermeglia, M., Gopal, Y. N. V., Yang, D., Podoloff, D. A., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0459 · Cited by 178
“However, BRAF mutations are extremely rare in other melanoma subtypes: acral lentiginous (AL), chronic sundamaged (CSD), and mucosal (4).”
BackgroundInfluential
Metadata
- Authors
- Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W. C., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., & Futreal, P. A.
- Affiliations
- Wellcome Sanger Institute (GB)
- Institute of Cancer Research (GB)
- Western Infirmary (GB)
- University of York (GB)
- Duke University (US)
- National Research Council (IT)
- University of Sassari (IT)
- Royal Brompton Hospital (GB)
- Queen Mary Hospital (CN)
- Abramson Cancer Center (US)
- Corresponding author
- Wooster, Richard
- ORCID
- Davies, Helen
- Edkins, Sarah
- Teague, Jon
- Garnett, Mathew J.
- Dicks, Ed
- Gray, Kristian
- Hughes, Jaime
- Kosmidou, Vivian
- Menzies, Andrew
- Watt, Stephen
- Hooper, Steven
- Shipley, Janet
- Hargrave, Darren
- Maitland, Norman
- Riggins, Gregory J.
- Bigner, Darell D.
- Palmieri, Giuseppe
- Cossu, Antonio
- Flanagan, Adrienne
- Nicholson, Andrew
- Ho, Judy W. C.
- Yuen, Siu T.
- Paterson, Hugh
- Marais, Richard
- Stratton, Michael R.
- Futreal, P. Andrew
- Venue
- Nature
- Published
- 2002-06
- Volume
- 417
- Issue
- 6892
- Pages
- 949-954
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2163188200
- Cited by
- 10,674
- References
- 24
- Citations by year
- 2026: 221 · 2025: 282 · 2024: 435 · 2023: 450 · 2022: 442 · 2021: 506 · 2020: 538 · 2019: 482 · 2018: 519 · 2017: 576 · 2016: 576 · 2015: 649 · 2014: 701 · 2013: 688 · 2012: 563
- FWCI
- 87.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BRAF mutation, somatic missense mutations, melanoma, oncogenic Ras, kinase activity, malignant transformation, therapeutic target
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cell Division, Cell Transformation, Neoplastic, DNA Mutational Analysis, Enzyme Activation, Humans, Melanoma, Molecular Sequence Data, Neoplasms, Tumor Cells, Cultured, 3T3 Cells, Protein Structure, Tertiary, ras Proteins, Proto-Oncogene Proteins c-raf, Mutation, Missense, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.